Dyne Therapeutics (NASDAQ:DYN) Receives Buy Rating from Chardan Capital

Chardan Capital reissued their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN) in a research report report published on Tuesday morning,Benzinga reports. The firm currently has a $50.00 price objective on the stock.

Several other analysts have also recently issued reports on the company. Oppenheimer initiated coverage on Dyne Therapeutics in a report on Monday, June 2nd. They issued an “outperform” rating and a $34.00 target price for the company. HC Wainwright dropped their price objective on shares of Dyne Therapeutics from $46.00 to $38.00 and set a “buy” rating for the company in a report on Friday, May 9th. Scotiabank began coverage on shares of Dyne Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $50.00 target price on the stock. JPMorgan Chase & Co. decreased their target price on shares of Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating on the stock in a report on Friday, March 21st. Finally, Raymond James Financial assumed coverage on shares of Dyne Therapeutics in a report on Wednesday, June 11th. They set an “outperform” rating and a $37.00 price target for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $44.93.

Dyne Therapeutics Trading Down 21.4%

DYN opened at $10.86 on Tuesday. Dyne Therapeutics has a twelve month low of $6.36 and a twelve month high of $47.45. The firm has a market capitalization of $1.23 billion, a PE ratio of -3.03 and a beta of 1.16. The firm’s 50-day moving average price is $11.40 and its 200 day moving average price is $14.86.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.17). As a group, analysts predict that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Dyne Therapeutics

Several institutional investors have recently bought and sold shares of the company. Rhumbline Advisers boosted its stake in shares of Dyne Therapeutics by 3.0% in the fourth quarter. Rhumbline Advisers now owns 128,244 shares of the company’s stock valued at $3,021,000 after purchasing an additional 3,734 shares during the period. Handelsbanken Fonder AB lifted its holdings in Dyne Therapeutics by 16.6% during the 4th quarter. Handelsbanken Fonder AB now owns 22,500 shares of the company’s stock worth $530,000 after buying an additional 3,200 shares in the last quarter. Arcadia Investment Management Corp MI boosted its position in Dyne Therapeutics by 16.4% in the 4th quarter. Arcadia Investment Management Corp MI now owns 44,940 shares of the company’s stock valued at $1,059,000 after buying an additional 6,326 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Dyne Therapeutics by 0.3% in the fourth quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company’s stock worth $5,532,000 after acquiring an additional 698 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Dyne Therapeutics by 2.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 667,452 shares of the company’s stock worth $15,725,000 after acquiring an additional 18,800 shares in the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.